Document Detail


Hairy cell leukemia: evaluation of the long-term outcome in 121 patients.
MedLine Citation:
PMID:  20597132     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Historically, the first treatment choices for hairy cell leukemia (HCL) were splenectomy and alpha-interferon. Recently, purine analogues (pentostatin and cladribine) changed radically the treatment modality, inducing complete and durable responses in the majority of patients.
METHODS: The authors analyzed the outcome of different lines of therapy in 121 HCL patients followed in their institute from 1986 to 2008, with a median follow-up of 105 months. Patients were divided into subgroups according to the number of treatments; Group A included 121 patients who underwent a front-line therapy, Group B patients (n =53) were treated with 2 lines, Group C patients (n = 34) with 3 lines, Group D patients (n = 17) with 4 lines, and Group E patients (n = 8) with 5 lines.
RESULTS: In Group A, 92 (77%) patients obtained a complete response (CR), 23 (18%) a partial response, and the remaining 6 (5%) a minor or no response; median duration of response was 2.7 years. In Group B, 53 relapsed patients achieved a second CR rate of 73.5%; median duration of response was 2.5 years. Group C contained 34 patients in a second relapse, with a CR rate after the third line of treatment of 70.5% (median duration of response, 2.2 years). In Group D, 11 (64.7%) patients obtained a CR (median duration of response, 1.6 years), and in Group E 4 (50%) of 8 patients achieved a CR (median duration of response, 1.3 years).
CONCLUSIONS: This study confirms the high risk (>40% of all patients) of retreatment of HCL patients and the need to maximize primary response.
Authors:
Pier Luigi Zinzani; Cinzia Pellegrini; Vittorio Stefoni; Enrico Derenzini; Letizia Gandolfi; Alessandro Broccoli; Lisa Argnani; Federica Quirini; Stefano Pileri; Michele Baccarani
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cancer     Volume:  116     ISSN:  0008-543X     ISO Abbreviation:  Cancer     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-10-06     Completed Date:  2010-11-16     Revised Date:  2010-12-07    
Medline Journal Info:
Nlm Unique ID:  0374236     Medline TA:  Cancer     Country:  United States    
Other Details:
Languages:  eng     Pagination:  4788-92     Citation Subset:  AIM; IM    
Copyright Information:
© 2010 American Cancer Society.
Affiliation:
Institute of Hematology and Medical Oncology "L. e A. Seragnoli," University of Bologna, Bologna, Italy. pierluigi.zinzani@unibo.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
2-Chloroadenosine / analogs & derivatives*,  therapeutic use
Adult
Aged
Aged, 80 and over
Antimetabolites, Antineoplastic / therapeutic use*
Deoxyadenosines / therapeutic use*
Disease-Free Survival
Drug Administration Schedule
Female
Humans
Leukemia, Hairy Cell / therapy*
Male
Middle Aged
Retreatment
Splenectomy
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antimetabolites, Antineoplastic; 0/Deoxyadenosines; 115044-75-2/2-chloro-3'-deoxyadenosine; 146-77-0/2-Chloroadenosine
Comments/Corrections
Comment In:
Expert Rev Hematol. 2010 Dec;3(6):679-83   [PMID:  21091144 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Lung cancer histology, stage, treatment, and survival in American Indians and Alaska Natives and whi...
Next Document:  Data and trends in cancer screening in the United States: results from the 2005 National Health Inte...